Janux Therapeutics Inc. (JANX)
JANX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1817713/000119312526076918/0001193125-26-076918-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | JANX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001817713 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $10.0M |
| Net income | -$113.6M |
| Operating income | -$157.7M |
| Net margin | -1136.3% |
| Operating margin | -1576.7% |
| Revenue growth | -5.6% |
| Cash | $52.3M |
| Total assets | $1.0B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 66.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $41.8M cash; operating cash flow -$13.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 61,183,417 (2026-11-03); 60,147,807 a year earlier; 46,168,430 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.3M | -$21.6M | -$25.2M | $41.8M | No debt tags | $23.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $10.3M | -$22.0M | $12.5M | $27.8M | No debt tags | $24.0M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $3.7M | -$24.4M | -$12.3M | $51.8M | No debt tags | $13.7M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$31.9M | -$28.5M | $52.3M | No debt tags | $10.0M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $10.0M | -$24.3M | -$12.9M | $48.4M | No debt tags | $10.0M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $0 | -$33.9M | -$23.8M | $52.4M | No debt tags | $439K | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $0 | -$23.5M | -$17.0M | $73.7M | No debt tags | $9.3M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $0 | -$20.2M | -$16.7M | $430.6M | No debt tags | $10.6M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-12-05 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 443 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -35.5% |
| 1 month | -33.8% |
| 3 months | -28.9% |
| Year to date | -17.6% |
| 1 year | -58.6% |
| From 52-week high | -67.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALMS | Alumis Inc. | $5.14 | -8.21% | $667.3M |
| APMD | Apnimed Inc. | $16.28 | -3.78% | $677.7M |
| NVCT | Nuvectis Pharma Inc. | $19.11 | -5.58% | $657.2M |
| ANNX | Annexon Inc. | $3.57 | -8.93% | $681.0M |
| KURA | Kura Oncology Inc. | $7.09 | -8.75% | $651.4M |
| BCAX | Bicara Therapeutics Inc. | $9.75 | -2.69% | $647.3M |
| ANL | Adlai Nortye Group Ltd. | $10.03 | -5.47% | $645.9M |
| OLMA | Olema Oncology Inc. | $7.36 | -2.65% | $644.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier